Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial

D. Lipson (Pennsylvania, United States of America), F. Barnhart (Research Triangle Park, United States of America), I. Boucot (Brentford, United Kingdom), C. Crim (Research Triangle Park, United States of America), N. Brealey (Uxbridge, United Kingdom), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, United States of America), D. Halpin (Exeter, United Kingdom), S. Kilbride (Uxbridge, United Kingdom), M. Han (Ann Arbor, United States of America), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Singh (Manchester, United Kingdom), I. Naya (Brentford, United Kingdom), C. Jones (Research Triangle Park, United States of America), R. Wise (Baltimore, United States of America)

Source: International Congress 2018 – COPD management
Session: COPD management
Session type: Thematic Poster
Number: 4384
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Lipson (Pennsylvania, United States of America), F. Barnhart (Research Triangle Park, United States of America), I. Boucot (Brentford, United Kingdom), C. Crim (Research Triangle Park, United States of America), N. Brealey (Uxbridge, United Kingdom), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, United States of America), D. Halpin (Exeter, United Kingdom), S. Kilbride (Uxbridge, United Kingdom), M. Han (Ann Arbor, United States of America), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Singh (Manchester, United Kingdom), I. Naya (Brentford, United Kingdom), C. Jones (Research Triangle Park, United States of America), R. Wise (Baltimore, United States of America). Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. 4384

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: